



Monitor respiratory health using voice

Arianna Arienzo, CEO





Asthma

80%

do not have the disease under **control**¹.

2/3 +

preventable deaths^{2,3}


28.8B€

of economic loss /year in EU⁴

Our solution










Al to measure asthma from the smartphone


Multi-stakeholder data value chains



Our app



Other platforms









Business model




covered by the healthcare system

Quality Clinical studies Medical device Data Listed in Management acquisition software EU Germany to train Al covered health System regulation ISO 13485 algorithms apps (DIGA) **IRCCS** CES Partner onboard

Revenues model



+1000 users since launch in January




Monthly subscription

€15/month

Target market





Market alternatives













myAsthma















Smart Asthma









Routine for self-care




Scalable as a standalone app



Our team

NTT Data





8 full time with in-house data scientists

ĽORÉAĽ

accenture

Our awards











Healthcare Start-up of the Year

EU

























Organizations

Luxembourg and Italy

Industry









Everyone, everywhere is empowered with knowing their well-being

contact@voicemed.io








Backup slides

How does B2C2B work?





Why B2B2C is popular model for digital health?



Consumer trends

- Increasingly tech-forward consumers
- More out-of-pocket spend

Business trends

- Vendor fatigue (CHRO, CIO)
- Raising bar for validation

Go-To-Market



PATIENTS

- Digital marketing & blog
- Influencers
- Patient
 associations &
 online
 communities
 (Asthma & lungs
 UK, Respiriamo
 insieme)
- Pharmacists

CLINICIANS

- Our network
- GP & pulmonologists associations
- Events (ERS, DMEA...)
- Large clinics
- Publications

HEALTH SYSTEMS

- Direct contacts with insurances (linkedin)
- Network (5HT, SHS)
- Open innovation opportunities with insurances
- Scale with DIGA


Market - Assumptions

VoiceMed

- 64% Age group 15-65,
- 80% Uncontrolled & partially controlled asthma
- €1200 extra cost per asthma patient
- 10% VoiceMed could save



Financial metrics (Revenues & EBITDA)



With Reach we will be able to grow fast









Mockup and

- MVP of DVC: empower asthma and share results with doctors
- New European Al reg. and Interoperability Standards

Investment Readiness Level

EXPERIMENT



Thank you!